Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma-Reference-Cited by-同舟云学术

Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma

Published:2014-03-07 Issue:10 Volume:55 Page:2335-2340
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dakhil Shaker,Hermann Robert,Schreeder Marshall T.,Gregory Stephanie A.,Monte Marc,Windsor Kevin S.,Hurst Deborah,Chai Akiko,Brewster Michael,Richards Paul

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.877135

Reference12 articles.

1. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

3. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

4. Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease;Journal of Oncology Pharmacy Practice;2024-06-07

2. Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-04-22

3. A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma;Japanese Journal of Clinical Oncology;2024-01-25

4. Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima);eJHaem;2023-10-17

5. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis;HemaSphere;2023-03-30